Xencor — Third Quarter 2026 Earnings Summary

Xencor reported a net income of $39.4 million for the third quarter of 2026, driven by $116.5 million in revenue from royalties and milestones. The company's lead candidate, XmAb819, demonstrated a 45.5% confirmed objective response rate in advanced clear cell renal cell carcinoma, with plans to initiate a Phase 3 study by the end of 2027. Additional pipeline updates include early dose-escalation data for plamotamab in rheumatoid arthritis and healthy participant data for the bispecific antibody XmAb412 expected in the first half of 2027. As of September 30, 2026, Xencor held $555.7 million in cash and marketable securities, providing sufficient funding to support operations through 2029.